| Beova (vibegron) / Merck (MSD), Kissei, Kyorin, Sumitomo Pharma, Pierre Fabre |
BEST, NCT05806164: Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence |
|
|
| Recruiting | 4 | 432 | US | Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox], Botox | Women and Infants Hospital of Rhode Island, University of New Mexico, University of Alabama at Birmingham, University of California, San Diego, Howard University, Brown University, Patient-Centered Outcomes Research Institute | Urgency Urinary Incontinence | 07/26 | 07/27 | | |
2018-003136-72: A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) |
|
|
| Not yet recruiting | 3 | 300 | Europe | Vibegron, URO-901, RVT-901, Film-coated tablet | Urovant Sciences GmbH, Urovant Sciences GmbH | Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH), Overactive bladder (OAB), Diseases [C] - Symptoms and general pathology [C23] | | | | |
NCT03902080 / 2018-003135-30: Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) |
|
|
| Completed | 3 | 1105 | Europe, Canada, US | Vibegron, RVT-901, MK-4618, KRP-114V, URO-901, Placebo | Urovant Sciences GmbH, Urovant Sciences GmbH | Overactive Bladder | 06/23 | 06/23 | | |
2018-003135-30: Study to evaluate vibegron in men taking stable BPH medications who have overactive bladder symptoms |
|
|
| Not yet recruiting | 3 | 1088 | Europe | Vibegron, URO-901, RVT-901, Film-coated tablet | Urovant Sciences GmbH, Urovant Sciences GmbH | Overactive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH), Overactive bladder (OAB), Diseases [C] - Symptoms and general pathology [C23] | | | | |
| Recruiting | 2/3 | 85 | US | Vibegron | Urovant Sciences GmbH, Urovant Sciences GmbH | Neurogenic Detrusor Overactivity | 01/27 | 09/27 | | |
| Recruiting | 1 | 75 | US | Placebo, Propranolol, Gemtesa | University of Missouri-Columbia | Aging, Menopause, Hypoxia, Vasodilation | 07/25 | 07/25 | | |
NCT05067478: Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB) |
|
|
| Completed | N/A | 403 | US | Vibegron, GEMTESA | Urovant Sciences GmbH | Overactive Bladder | 07/24 | 07/24 | | |
NCT06438861: Role of Combination Therapy in Women With Refractory Overactive Bladder |
|
|
| Not yet recruiting | N/A | 54 | NA | Vibegron 75mg, Placebo | University of Alabama at Birmingham | Overactive Bladder Syndrome | 10/25 | 01/26 | | |
